Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Debt (2016 - 2017)

Historic Non-Current Debt for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Q4 2017 value amounting to $18000.0.

  • Lineage Cell Therapeutics' Non-Current Debt fell 8500.0% to $18000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $18000.0, marking a year-over-year decrease of 8500.0%. This contributed to the annual value of $18000.0 for FY2017, which is 8500.0% down from last year.
  • As of Q4 2017, Lineage Cell Therapeutics' Non-Current Debt stood at $18000.0, which was down 8500.0% from $44000.0 recorded in Q3 2017.
  • Lineage Cell Therapeutics' 5-year Non-Current Debt high stood at $268000.0 for Q3 2015, and its period low was $18000.0 during Q4 2017.
  • Its 3-year average for Non-Current Debt is $142600.0, with a median of $146500.0 in 2016.
  • In the last 5 years, Lineage Cell Therapeutics' Non-Current Debt plummeted by 3544.78% in 2016 and then tumbled by 8500.0% in 2017.
  • Lineage Cell Therapeutics' Non-Current Debt (Quarter) stood at $220000.0 in 2015, then crashed by 45.45% to $120000.0 in 2016, then tumbled by 85.0% to $18000.0 in 2017.
  • Its last three reported values are $18000.0 in Q4 2017, $44000.0 for Q3 2017, and $95000.0 during Q2 2017.